126 related articles for article (PubMed ID: 18408655)
1. NM23 as a prognostic biomarker in ovarian serous carcinoma.
Youn BS; Kim DS; Kim JW; Kim YT; Kang S; Cho NH
Mod Pathol; 2008 Jul; 21(7):885-92. PubMed ID: 18408655
[TBL] [Abstract][Full Text] [Related]
2. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
Ricciardelli C; Lokman NA; Cheruvu S; Tan IA; Ween MP; Pyragius CE; Ruszkiewicz A; Hoffmann P; Oehler MK
Clin Exp Metastasis; 2015 Jun; 32(5):441-55. PubMed ID: 25895698
[TBL] [Abstract][Full Text] [Related]
3. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters.
Arik D; Kulaçoğlu S
Turk Patoloji Derg; 2011 Jan; 27(1):38-45. PubMed ID: 21469425
[TBL] [Abstract][Full Text] [Related]
4. nm23 expression in malignant ascitic effusions of serous ovarian adenocarcinoma.
Simone G; Falco G; Caponio MA; Campobasso C; De Frenza M; Petroni S; Wiesel S; Leone A
Int J Oncol; 2001 Nov; 19(5):885-90. PubMed ID: 11604983
[TBL] [Abstract][Full Text] [Related]
5. Increased Expression of Holliday Junction-Recognizing Protein (HJURP) as an Independent Prognostic Biomarker in Advanced-Stage Serous Ovarian Carcinoma.
Li L; Li X; Meng Q; Khan AQ; Chen X
Med Sci Monit; 2018 May; 24():3050-3055. PubMed ID: 29743473
[TBL] [Abstract][Full Text] [Related]
6. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma.
Srivatsa PJ; Cliby WA; Keeney GL; Dodson MK; Suman VJ; Roche PC; Podratz KC
Gynecol Oncol; 1996 Mar; 60(3):363-72. PubMed ID: 8774640
[TBL] [Abstract][Full Text] [Related]
7. [A study on C-erbB2, nm23 and p53 expressions in epithelial ovarian cancer and their clinical significance].
Liu L; Yang K
Zhonghua Fu Chan Ke Za Zhi; 1999 Feb; 34(2):101-4. PubMed ID: 11263193
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
[TBL] [Abstract][Full Text] [Related]
11. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
12. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
13. The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer.
Baekelandt M; Holm R; Tropé CG; Nesland JM; Kristensen GB
Ann Oncol; 1999 Nov; 10(11):1335-41. PubMed ID: 10631462
[TBL] [Abstract][Full Text] [Related]
14. Correlation between NM23 protein overexpression and prognostic value and clinicopathologic features of ovarian cancer: a meta-analysis.
Fang J; Guo X; Zheng B; Han W; Chen X; Zhu J; Xie B; Liu J; Luan X; Yan Y; He Z; Li H; Qiao C; Yu J
Arch Gynecol Obstet; 2018 Feb; 297(2):449-458. PubMed ID: 29274004
[TBL] [Abstract][Full Text] [Related]
15. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
[TBL] [Abstract][Full Text] [Related]
16. Expression of cyclooxygenase-2 in ovarian serous carcinoma: correlation with angiogenesis, nm23 expression and survival.
Ozuysal S; Bilgin T; Ozgur T; Celik N; Evrensel T
Eur J Gynaecol Oncol; 2009; 30(6):640-5. PubMed ID: 20099494
[TBL] [Abstract][Full Text] [Related]
17. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
[TBL] [Abstract][Full Text] [Related]
18. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
[TBL] [Abstract][Full Text] [Related]
19. Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis.
Liu H; Wang A; Ma Y
Biomed Res Int; 2020; 2020():1392674. PubMed ID: 33299855
[TBL] [Abstract][Full Text] [Related]
20. CD44 Immunoexpression is Unfavorable Predictor in Ovarian Serous Cancer.
Karan Križanac D; Krasić Arapović A; Skočibušić S; Pintarić I; Trgo G; Tomić S
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):398-402. PubMed ID: 27490763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
